What is the current Global Hereditary Angioedema Therapeutics Market size?

The Global Hereditary Angioedema Therapeutics Market is projected to register a CAGR of 8.5% during the forecast period (2025-2030) Read More

What is the current size of the hereditary angioedema therapeutics market?

The market was valued at USD 5.86 billion in 2025 and is projected to reach USD 12.79 billion by 2030. Read More

Which region is expected to post the fastest growth through 2030?

Asia-Pacific is forecast to expand at a 17.8% CAGR, outpacing all other regions. Read More

Which treatment class holds the largest revenue share today?

C1 esterase inhibitors accounted for 61.3% of global revenue in 2024. Read More

How quickly are oral kallikrein inhibitors growing?

Oral kallikrein inhibitors are advancing at a 19.5% CAGR, supported by strong uptake of berotralstat. Read More

What are typical annual therapy costs for hereditary angioedema patients?

Annual prophylaxis costs frequently exceed USD 500,000 per patient, posing budget pressure for payers. Read More

Which companies dominate the competitive landscape?

CSL Behring, Takeda, and BioCryst collectively controlled just over 60% of 2024 global revenue. Read More

Global Hereditary Angioedema Therapeutics Companies

This report lists the top Global Hereditary Angioedema Therapeutics companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Global Hereditary Angioedema Therapeutics industry.